Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China

Zhihui Zhang, MD, PhD, Peng Yuan, MD, PhD, Huiqin Guo, MD, PhD, Linlin Zhao, MT, Jianming Ying, MD, PhD, Mingrong Wang, PhD, Huan Zhao, MD, PhD, Qinjing Pan, MD, and Binghe Xu, MD, PhD

Abstract: Estrogen receptor (ER) and progesterone receptor (PR) overexpression can be used to predict patient prognosis in breast cancer (BC). Human epidermal growth factor receptor 2 (HER2) is a reliable predictive marker in invasive breast cancer (IBC). Thin-Prep (TP) specimens are commonly utilized for immunocytochemistry (ICC) in fine needle aspiration cytology (FNAC). Thus, we sought to investigate if the incorporation of molecular diagnosis performed on TP-processed specimens is applicable in clinical practice.

Hormone receptors (HRs) and HER2 immunocytochemistry was performed on 542 primary breast cancer FNAC specimens using the TP method. One hundred fourteen HER2 fluorescence in situ hybridization (FISH) analyses were performed on HER2 ICC 2+ FNAC specimens and the corresponding tissue samples. HRs results of TP slides and those of formalin-fixed paraffin-embedded (FFPE) slides were correlated well for ER (concordance rate = 93.3%, kappa value = 0.85) and PR (concordance rate = 88.6%, kappa value = 0.75). HER2 results for the TP slides and those of the matched FFPE slides also correlated well (concordance rate = 80.0%, kappa value = 0.62). The specificity of HER2 was 97.3%; however, the sensitivity was only 67.1%. Cytological specimens and histological samples showed a strong correlation (concordance rate = 99.1%, kappa value = 0.98) while being used to evaluate HER2 gene amplification.

FNAC is a minimally invasive technique that can be used as an alternative method to collect tissue especially in cases where an excisional or core biopsy is difficult to obtain, or when recurrence is present. The results of ICC HRs in FNAC TP specimens may be used instead, but HER2 assessment may not be reliable enough for clinical use. FISH testing is necessary in this setting.

INTRODUCTION

As a simple and rapid procedure in the diagnosis of breast cancers, fine needle aspiration cytology (FNAC) can provide a reliable and accurate approach for diagnosis of breast carcinoma. Meanwhile, it can be used as an alternative method to collect tissue from patients with inoperable, metastatic, or recurrent breast carcinomas. Immunocytochemistry (ICC) and molecular tests can also be performed on cytological materials to assess prognosis and predict treatment outcome of patients.

The Thin-Prep (TP) cytology (Hologic Corp., Marlborough, MA) procedure was recently developed for ICC and molecular diagnosis. Compared to conventional smears, a single specimen can generate multiple slides by using TP, and a minimal amount of reagent is required in the ICC procedure because the specimens tend to be small in size.1–3 Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are among those most well-established and extensively studied biomarkers for invasive breast cancer (IBC).4–7 According to the guidelines published by American Society of Clinical Oncology/Colege of American Pathologists (ASCO/CAP), immunohistochemistry (IHC) has been a commonly used method to detect the overexpression of hormone receptors (HRs) and HER2 in formalin-fixed paraffin-embedded (FFPE) tissue slides, while fluorescence in situ hybridization (FISH) is an alternative standard test for gene amplification of HER2.8–10 Assessment of these biomarkers with ICC on FNAC specimens has been studied extensively on direct smears and cell block (CB) slides, with variably concordant rates.11,12 However, very limited number of studies were conducted to evaluate the correlation of HR levels, HER2 protein overexpression, and gene amplification in FFPE tissues and TP slides of IBC.

The objective of this article was to detect if tissue collected with FNAC and processed using the TP method can be an alternative specimen for molecular diagnosis (HRs and HER2 status assessment) in primary and metastatic IBC.

Abbreviations: ASCO = American Society of Clinical Oncology, CAP = College of American Pathologists, CB = cell block, DCIS = ductal carcinoma in situ, ER = estrogen receptor, FFPE = formalin-fixed paraffin-embedded, FISH = fluorescence in situ hybridization, FNAC = fine needle aspiration cytology, HER2 = human epidermal growth factor receptor 2, HR = hormone receptor, IBC = invasive breast cancer, ICC = immunocytochemistry, IHC = immunohistochemistry, PR = progesterone receptor, TP = thin-prep.
MATERIALS AND METHODS

Patients

A total of 542 patients were enrolled into this study. This population included patients who were diagnosed with breast carcinoma from June 2010 to July 2013 at the Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China. All patients were subjected to diagnostic FNAC by standard technique, with subsequent cytological evaluation.

FNAC biopsies were performed with 22 gauge needles. Four to 5 TP slides were prepared on the basis of the number of cells of different samples. One of them was used for HER2 detection and 2 of them were used for HRs, both by ICC method. The remaining specimens were stored at −80°C for additional HER2 gene test, if necessary (see below).

All 542 TP slides have the corresponding histologic specimens for comparison and analysis. The histological samples were fixed in 10% neutral-buffered formalin for 6 to 72 hours. Staining and diagnosis were performed in terms of the routine procedures. Three tissue sections were utilized for IHC evaluation of HRs and HER2. One tissue section was used for FISH, if it was deemed necessary.

This study is retrospective and the data were analyzed anonymously. No images and private information of the patients were released. The Institute Review Board of the Chinese Academy of Medical Sciences, Beijing, China approved the study protocol and agreed to waive the need for consent by the patient.

ER, PR, and HER2 Immunocytochemistry

Immunocytochemical staining for HRs was performed on FNAC TP preparations and on tissue sections with the avidin–biotin–peroxidase method, using the anti-ER, anti-PR, and anti-HER2 antibodies (mouse monoclonal antibody, procured by Zymed, San Diego, California, USA).

TP preparations were firstly fixed in 95% alcohol for 30 minutes. After the slides were taken out and dried, they were incubated with 3% H₂O₂ and then with normal serum overnight at 4°C with the primary antibody. The slides were then incubated with the biotinylated secondary antibody (Zymed, Invitrogen Corp., CA), and conjugated the avidin–biotin–peroxidase complex (PV9000, Zymed). The reaction was developed using 3,3′-diaminobenzidine (Zymed). With regard to the tissue slides, they were firstly deparaffinized in xylene and then rehydrated in an alcohol gradient. The procedures going forward for tissue slides were the same as those of TP slides. All slides were counterstained with hematoxylin and mounted for microscopic examination. The known positive tissue specimens (breast) of patients were used as positive controls, and the PBS, as the substitute for the primary antibody, were used as the negative controls.

Nuclear staining of the cancer cells was regarded as positive according to the percentage of stained cells seen on cytological and histological slides. The cutoff value was 1% in terms of the ASCO/CAP guidelines for HRs of breast cancer and each sample included a negative control antibody.

HER2 status was evaluated by ICC in terms of the ASCO/CAP guidelines. In brief, those samples, whose membrane has no staining or partial staining, which is not complete and faintly/barely observed in ≤10% of tumor cells, were defined as 0; partial membrane staining, which is faintly/barely observed in >10% of tumor cells, was defined as 1++; circular membrane staining, which is not complete and/or weak/moderate in >10% of tumor cells, or complete and circular membrane staining, which is intense in ≤10% of tumor cells, were defined as 2+; circular membrane staining, which is complete in >10% of tumor cells, were defined as 3+. Those samples were regarded as negative if their staining scores were 0 and 1+. The samples with staining scores of 2+ and 3+ were regarded as equivocal and positive, respectively. All cases were observed blindly and independently by 2 pathologists; discrepant results were resolved by joint review. Additional FISH tests were performed on immune-staining cases scored as 2+, for the purpose of evaluating the gene status.

FISH Analysis for HER2 Amplification

The commonly used dual-probe PathVysion kit (Abbott Molecular, Des Plaines, IL) was chosen to assess HER2 gene status on FFPE samples and TP preparations, which are performed by similar procedures. But FNAC TP preparations were no longer necessary for deparaffinization and the initial hydrochloric acid treatment. After counterstained with 4,6-diamidino-2-phenylindole (DAPI), all slides were mounted for microscopic examination. In order to calculate the ratio of orange signals (the HER2 gene)/green signals (chromosome enumeration probe 17, CEP-17), all samples were observed by means of fluorescence microscope (Olympus U-TV0.63×C 9A05367, Japan; 1000× magnification) with 3 filters DAPI, Spectrum Orange, and Spectrum Green.

HER2 gene amplification status was determined based on the ASCO/CAP guidelines. In each sample, 20 cells were counted and the ratio of HER2 to CEP17 was calculated. The HER2 gene was considered amplified if the HER2/CEP17 ratio ≥2.0 or HER2/CEP17 ratio <2.0 but average HER2 copy number ≥6.0 per cell. The HER2 gene status was considered equivocal if the HER2/CEP17 ratio <2.0 but average HER2 copy number >4.0 while <6.0 per cell. The HER2 gene was considered not amplified if the HER2/CEP17 ratio <2.0 and average HER2 copy number <4.0 per cell. All cases were evaluated blindly and independently by 2 pathologists; discrepant results were reconsidered by joint review.

Statistical Analysis

The HRs and HER2 overexpression was detected on the cytological and histological specimens for each case. The McNemar test was applied to assess whether similar results were generated by the 2 methods. If the obtained P values were less than 0.05, they were regarded as significant.

The Cohen kappa statistic was utilized to assess the agreement between the cytological and histological slides. Kappa values >0.6 mean that the agreement was good. Kappa values >0.8 mean that the agreement was very good. In the procedure of analysis, only the cases in which the status of the considered markers was capable of being assessed in both by TP preparations and the matched tissue samples were evaluated. All statistical analyses were carried out using the Statistical Analysis System.

RESULTS

In this study, all enrolled patients were women ranging in age from 26 to 95 years (mean, 53 years). The majority (97.9%) had invasive ductal carcinoma; the most frequent histological grades were 2 and 3. The amount of ductal cancer in situ (DCIS) was observed on the tissue slides, DCIS components were not observed in 499 samples of the total. The remaining 43 samples
TABLE 1. Pathologic and Clinical Characteristics of the Cases

| Characteristic                  | No. of Cases or Patients, % |
|--------------------------------|-----------------------------|
| Histotype                      |                             |
| Invasive ductal carcinoma       | 537 (99.1)                  |
| Invasive mucinous carcinoma     | 5 (0.9)                     |
| Ductal carcinoma in situ        |                             |
| Absent                         | 499 (92.1)                  |
| <25%                           | 30 (5.5)                    |
| >25%                           | 13 (2.4)                    |
| Tumor diameter                 |                             |
| >2 cm                          | 417 (76.9)                  |
| <2 cm                          | 125 (23.1)                  |
| Lymph node                     |                             |
| Positive                       | 249 (45.9)                  |
| Negative                       | 293 (54.1)                  |

that were diagnosed as invasive ductal carcinoma showed in situ components. Thirty cases comprised a DCIS component of less than 25% in each case of lesion. Only 13 samples were found comprising DCIS component larger than 25% in each case of lesion. The majority of the cases showed with tumors having >2 centimeters (76.9%) of their maximum diameter, and 249 (45.9%) cases were positive for lymph node metastases. Meanwhile, 43 out of 542 cases (7.9%) were diagnosed as invasive ductal carcinoma which showed in situ component. Thus, we always obtain samples in the middle of the tumor masses, avoiding peripheral DCIS area (see Table 1).

The HRs and HER2 status of all 542 FFPE specimens and the corresponding satisfactory TP specimens were assessed by IHC and ICC, respectively (Table 2). Among the 542 TP specimens, the slides with cell number ≥100 were considered satisfactory and included in this analysis. In total, 520 slides for ER, 517 slides for PR, and 529 slides for HER2 status analysis were included in this analysis (see Figure 1A, B). Twenty two TP specimens were not assessable for ER expression due to unsatisfactory quality and included in this analysis. In total, 520 slides for ER, 517 slides for PR, and 529 slides for HER2 status analysis were included in this analysis (Table 2). As shown in Table 3, the positive rates of ER in TP and FFPE specimens were 63.2% and 66.2%, respectively (P = 0.0001); and those of PR were 65.9% and 67.1%, respectively (P = 0.0001). The positive rates of HER2 were 39.7% and 97.3%, respectively (P < 0.0001), which was statistically significant.

**ER Status**

Total 520 pairs of samples possess results of ER expression for both TP slides and corresponding FFPE tissue specimens (see Figure 1A, B). Twenty two TP specimens were not assessable for ER expression due to unsatisfactory quality (Table 2). For the 485 of the 520 samples, our evaluation results of the TP-processed samples correlated well (concordance rate = 93.3%, kappa = 0.85) with those of the tissue slides. The sensitivity of ER assessment was 94.7%, and the specificity was 90.7%. There were 35 discordant results. The differences of the assessment of the ER overexpression between the 2 methods were not statistically significant (P = 0.8618) (Table 4).

**PR Status**

Among the 542 TP specimens, 25 cases were not assessable (Table 2). There were total 517 pairs of samples had PR status results for both TP and corresponding FFPE tissue specimens (see Figure 1C, D). For the 458 of the 517 samples, our evaluation results of the TP-processed samples correlated well (concordance rate = 88.6%, kappa = 0.75) with those of the tissue slides. The sensitivity of PR status was 91.4%, and the specificity was 83.1%. There were 59 discordant results. The differences of the assessment of the PR overexpression between the 2 methods were not statistically significant (P = 0.8907) (Table 5).

**HER2 Status**

For HER2 status assessment, 13 cases were not assessable from TP specimens (Table 2). So, there were 529 pairs of samples that had results for both FNAC and the tissue samples (see Figure 1E, F). The evaluation results of TP preparation correlated well with those of the tissue slides in 423 of the 529 samples (concordance rate = 80.0%, kappa = 0.62) (Table 6). The agreement cases in positive expression between 2 methods were 204. One hundred fourteen cases express a score of 2+ in TP specimens. The HER2 sensitivity and specificity were 67.1% and 97.3%, respectively. There were 106 discordant results. The positive predictive value was 97.1%, and the negative predictive value was 68.8%. The differences observed between the 2 methods when used to evaluate HER2 status were statistically significant (P < 0.0001).

**TABLE 2. Quality of Thin-Prep Slides**

| TP numbers | ER, % | PR, % | HER2, % |
|------------|-------|-------|---------|
| ≥100       | 520 (95.9) | 517 (95.4) | 529 (97.6) |
| <100       | 16 (3.0) | 18 (3.3) | 8 (1.5) |
| Slipped    | 6 (1.1) | 7 (1.3) | 5 (0.9) |
| Total      | 542   | 542   | 542     |

ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, PR = progesterone receptor, TP = Thin-Prep.

**TABLE 3. Immunohistochemical Results of Hormone Receptors and Human Epidermal Growth Factor Receptor 2 Status in Thin-Prep Preparations and Formalin-Fixed Paraffin-Embedded Tissue Samples**

| Characteristic | TP | FFPE | χ² | P |
|----------------|----|------|----|---|
| ER, %          |    |      |    |   |
| Positive       | 328 (63.2) | 345 (63.7) | 0.0380 | 0.8455 |
| Negative       | 192 (36.8) | 197 (36.3) | 0.5480 | 0.4618 |
| Total          | 520 | 542  |    |   |
| PR, %          |    |      |    |   |
| Positive       | 340 (65.9) | 359 (66.2) | 0.0263 | 0.8712 |
| Negative       | 177 (34.1) | 183 (33.8) | 0.0858 | 0.7743 |
| Total          | 517 | 542  |    |   |
| HER2, %        |    |      |    |   |
| 3+             | 96 (18.1) | 129 (23.8) | 17.3877 | <0.0001 |
| 2+             | 114 (21.6) | 175 (32.5) | 17.3877 | <0.0001 |
| 1+/0           | 319 (60.3) | 238 (43.9) | 17.3877 | <0.0001 |
| Total          | 529 | 542  |    |   |

ER = estrogen receptor, FFPE = formalin-fixed paraffin-embedded, HER2 = human epidermal growth factor receptor 2, PR = progesterone receptor, TP = Thin-Prep.
HER2 FISH Results

Among the 529 FNAC TP samples with HER2 ICC results, 114 were scored 2+. Performing FISH assay with these ICC equivocal cases, we found that 41.2% (47/114) samples were HER2-amplified. FISH assay results of the corresponding FFPE samples revealed that 40.4% (46/114) were HER2-amplified (Figure 2A, B). Of these 114 pairs of specimens, 113 pairs showed concordant results (kappa = 0.98, P = 0.3173), showing high concordant rate between FNAC and FFPE FISH results (99.1%). In the discordant pair, FISH of the FFPE specimen indicated negative result for HER2 gene amplification, while that of the FNAC specimen was positive (HER2/CEP-17 = 1.3 vs HER2/CEP-17 = 4.2). Repeating FISH for this case showed similar result (HER2/CEP-17 = 1.5 in FFPE samples, HER2/CEP-17 = 3.8 in FNAC specimens) (Figure 3A, B, Table 7).

DISCUSSION

As an accurate and sensitive modality for obtaining diagnosis samples, FNAC has been increasingly used as a means in the diagnosis of breast cancer. The tissue collected is used for diagnostic purposes as well as for a multitude of ancillary tests including prognostic and predictive biomarkers. FNAC is a valuable alternative method to obtain specimens for diagnosis and evaluation of HRs and HER2 status and HER2 gene amplification. This method may be particularly beneficial for patients with lesions that are not amenable to excisional/core biopsies or for patients with inoperable or metastatic BC. Idirisinghe et al13 reported that different overexpression in HRs and HER2 status were observed in primary and metastatic cancer cells. Therefore, these biomarkers should be reevaluated before patients get further treatment. For recurrence and metastatic tumors, FNAC may be the optimal choice for obtaining tissue material since the operation is simpler and has relatively lower risk of complications than traditional tissue biopsies.14

The cytology specimens prepared by the TP method can be preserved for several months or even years. TP slides usually

### TABLE 4. Estrogen Receptor Status in Thin-Prep Preparations and the Corresponding Formalin-Fixed Paraffin-Embedded Tissue Specimens

| ER Status (TP) | ER Status (FFPE) | Total |
|---------------|-----------------|-------|
| Positive      | 318             | 335   |
| Negative      | 18              | 185   |
| Total         | 336             | 520   |

ER = estrogen receptor, FFPE = formalin-fixed paraffin-embedded, TP = Thin-Prep.

### TABLE 5. Progesterone Receptor Status in Thin-Prep Preparations and in the Corresponding Formalin-Fixed Paraffin-Embedded Tissue Specimens

| PR Status (TP) | Positive | Negative | Total |
|---------------|----------|----------|-------|
| PR Status (FPPE) |          |          |       |
| Positive      | 310      | 30       | 340   |
| Negative      | 29       | 148      | 177   |
| Total         | 339      | 178      | 517   |

FFPE = formalin-fixed paraffin-embedded, PR = progesterone receptor, TP = Thin-Prep.

### TABLE 6. Human Epidermal Growth Factor Receptor 2 Status in Thin-Prep Preparations and in the Corresponding Formalin-Fixed Paraffin-Embedded Tissue Specimens

| HER2 Status (TP) | HER2 Status (FFPE) | Total |
|-----------------|--------------------|-------|
| HER2 Status (FPPE) |                    |       |
| Positive        | 204                | 6     | 210   |
| Negative        | 100                | 219   | 319   |
| Total           | 304                | 225   | 529   |

FFPE = formalin-fixed paraffin-embedded, HER2 = human epidermal growth factor receptor 2, TP = Thin-Prep.
have a clear background, with less nonspecific staining and higher cell density, thus minimizing the antibodies used. Smears processed with the TP method provide high quality staining of cells which are easily assessed.15,16 Furthermore, several antibodies can be used on the same slide simultaneously, enhancing the efficiency of molecular diagnosis. Some latest reports about HRs protein overexpression and HER2 gene amplification assessment for breast cancer by ICC and FISH using FNAC specimens showed excellent concordance rates between FNAC slides and FFPE sections.17–24 The use of FNAC specimens in determining the HRs status and the level of HER2 gene amplification can achieve high sensitivity, accuracy, and reliability. In this study, we used diagnostic results of HRs and HER2 status of FFPE tissue specimens as the gold standard to investigate if molecular diagnosis with TP-processed specimens is applicable to clinical practice.

Our immune-staining data show very good concordance rates (ER status: 93.3%, PR status: 88.6%) and excellent consistency (ER status: kappa = 0.85, PR status: kappa = 0.75) by the Cohen kappa test between FNAC slides and the corresponding tissue sections, and no any statistically significant differences were found between the 2 methods by McNe mar test (ER status: P = 0.8618, PR status: P = 0.8907). These results are consistent with the findings in previous reports.17,18,24,25 Enrico et al evaluated the ER and PR status in 111 patients with BC by 2 methods, reporting concordance rates of 98.0% (kappa = 0.92) and 90.0% (kappa = 0.76), respectively. Our evaluation results were in line with those above that the assessment of HRs protein overexpression for TP specimens is basically at the same reliable level as tissue sections.

The reason for the false negative results upon rereading the TP slides is that although a small number of cells are positive in the slides, they are interpreted as negative due to their intermediate intensity. The reason for false positive results is that in some slides, both the cytoplasm and nuclei are stained. Thus, these slides are mistakenly judged as positive. Additionally, the heterogeneity of positive cells in the tumor is also one of the key

FIGURE 2. Fluorescence in situ hybridization (FISH) is shown for HER2 gene amplification on Thin-Prep (TP) specimens and on the corresponding histologic sections (A, B, DAPI staining). (A) HER2 gene amplification is shown on a TP cytology specimen (panel A, ×1000, FISH ratio, HER2/CEP-17 = 3.9). (B) HER2 gene amplification is shown on the corresponding histologic section (panel B, ×1000, FISH ratio, HER2/CEP-17 = 4.2).

FIGURE 3. A and B were showed for the same case (A, B, DAPI staining). Fluorescence in situ hybridization (FISH) on a Thin-Prep cytology specimen indicated positive result for HER2 gene amplification, while the same case histologic specimen indicated negative result. (panel A, B, ×1000, HER2/CEP-17 = 3.8, HER2/CEP-17 = 1.5).
The concordance rate between the HER2 protein overexpression and gene amplification of HER2 was 99.1% (kappa = 0.98, P = 0.3173), which is consistent with previous studies (98%–100%).19-21 Of the only pair of specimens with discordant result, the FPPE specimen was scored 2+ by IHC and diagnosed as negative for HER2 gene amplification by FISH (HER2/CEP-17 = 1.3), while the corresponding FNAC specimen was diagnosed as HER2 gene amplified by FISH (HER2/CEP-17 = 4.2). Histology test confirmed this case as a grade II infiltrating ductal carcinoma containing no in situ components. Since FISH is conducted on whole nuclei of FNAC specimens and truncation artifacts are avoided, it gives the most accurate assessments of gene and chromosome copy numbers, resulting in accurate gene/chromosome ratios. Nevertheless, the heterogeneity of tumor cells (various amplification ratios in different cells of the same tumor) may be a reason for this observation.34-36 Moreover, the results reported by Enrico et al24 showed that the shorter fixation time may influence HER2 results. It is worth noting that our specimens for HER2 gene amplification detection were preserved for 0.5 to 27 months, and results were not affected by the long storage time. This implied that TP-processed FNAC specimens could be stored for 2 years without substantially affecting results of FISH analysis.

In this study, we performed assessment of HR levels and HER2 protein expression in 542 TP-processed FNAC breast cancer specimens. The results of HR levels using FNAC specimens correlated well with those of FPPE specimens, with high sensitivity. HER2 ICC assessment using TP-processed FNAC specimens had lower sensitivity but high specificity, indicating that the positive results of HRs and HER2 ICC in FNAC specimens have good reliability for clinical use.

### TABLE 7. Comparison of Fluorescence In Situ Hybridization Results From 114 Immunocytochemistry Equivocal Fine Needle Aspiration Cytology Specimens and the Corresponding Formalin-Fixed Paraffin-Embedded Specimens

| HER2 FISH (FPPE) | HER2 FISH (FNAC) | Amplification | No Amplification | Total |
|------------------|------------------|---------------|------------------|-------|
| Amplification    | 46               | 1             | 47               |
| No amplification | 0                | 67            | 67               |
| Total cases      | 46               | 68            | 114              |

FPPE = formalin-fixed paraffin-embedded, FISH = fluorescence in situ hybridization, FNAC = fine needle aspiration cytology, HER2 = human epidermal growth factor receptor 2.
specimens were reliable for clinical diagnosis. Negative results of ICC, especially for HER2, in FNAC specimens were unreliable. However, FISH analysis for the 114 equivocal cases for HER2 ICC with TP-processed slides possesses high concordance rate with FFPE samples.

In conclusion, in the patients whose histology specimens are not easy to obtain or when recurrence is present, the results of ICC HRs in TP FNAC specimens may be reliable, but HER2 assessment is not reliable enough for clinical use. FISH testing is necessary in this setting.

REFERENCES

1. Kontozoglou K, Moulakakis KG, Konofaos P, et al. The role of liquid-based cytology in the investigation of breast lesions using fine-needle aspiration: a cytohistopathological evaluation. J Surg Oncol. 2005;89:75–78.

2. Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621–634.

3. Fadda G, Rossi ED, Mulé A, et al. Diagnostic efficacy of immunocytochemistry on fine needle aspiration biopsies processed by thin-layer cytology. Acta Cytol. 2006;50:129–135.

4. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735.

5. Osborne CK, Schiff R, Arpino G, et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005;14:458–465.

6. Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1727–1741.

7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.

8. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86–92.

9. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907–922.

10. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997–4013.

11. Brifiod M, Le Doussal V, Spyrratos F. Immunohistochemical determination of hormonal receptors on cell-blocks from fine-needle cytopunctures of breast carcinoma. Bull Cancer. 2001;88:1028–1035.

12. Veneti S, Daskalopoulos D, Zervoudis S, et al. Liquid-based cytology in breast fine needle aspiration. Comparison with the conventional smear. Acta Cytol. 2003;47:188–192.

13. Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010;133:416–429.

14. Zhang ZH, Zhao DB, Zhao LL, et al. The value of thin-layer cytology in intraoperative fine-needle aspiration biopsy of pancreatic cancer. Zhonghua Zhong Liu Za Zhi. 2008;30:476–479.

15. Tabbara SO, Sidawy MK, Frost AR, et al. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer. 1998;84:355–360.

16. Sauer T, Ebeltoft K, Pedersen MK, et al. Liquid based material from fine needle aspirates from breast carcinomas offers the possibility of long-time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal. 2010;7:24.

17. Konofaos P, Kontozoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006;15:257–266.

18. Nishimura R, Aogi K, Yamamoto T, et al. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011;458:153–158.

19. Beatty BG, Bryant R, Wang W, et al. HER2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246–255.

20. Bofin AM, Ytterhus B, Martin C, et al. Detection and quantitation of HER2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004;122:110–119.

21. Lee JW, Noh WC, Kim MS, et al. Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients. Korean J Lab Med. 2008;28:392–399.

22. Gu M, Ghafari S, Zhao M, et al. Fluorescence in situ hybridization for HER2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol. 2005;49:471–476.

23. Kapila K, Al-Awadhi S, Francis I. HER2 neu (Cerb-B2) expression in fine needle aspiration samples of breast carcinoma: a pilot study comparing FISH, CISH and immunocytochemistry. J Cytol. 2011;28:54–56.

24. Pegolo E, Machin P, Riosa F, et al. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma correlation with histologic sections determination. Cancer Cytopathol. 2012;120:196–205.

25. Domanski MJ, Monsef N, Domanski HA, et al. Comparison of the estrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology. 2013;24:21–25.

26. Durgapal P, Mathur SR, Kalamuddin M, et al. Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smear: experience from a tertiary care centre in India. Diagn Cytopathol. 2014;42:726–731.

27. Moniki T, Takahashi T, Ueta S, et al. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinomas: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251–256.

28. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11:4741–4748.

29. Tan YO, Han SW, Lu YS, et al. The prevalence and assessment of HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology. 2013;24:21–25.

30. Bueno Angela SP, Viero RM, Soares CT, et al. Fine needle aspirate cytology in breast fine needle aspiration. Comparison with the conventional smear. Cancer Cytopathol. 2012;120:196–205.

31. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11:4741–4748.
growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. *Diagn Cytopathol.* 2013;41:192–198.

32. Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? *Oncol Rep.* 2006;15:803–808.

33. Bedard YC, Pollett AF, Leung SW, et al. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. *Acta Cytol.* 2003;47:979–984.

34. Halimi M, Aghbali AA, Tabrizi AD, et al. Expression of epidermal growth factor receptor tyrosine kinase family in fine needle aspiration and permanent specimens of invasive lobular and ductal breast cancers. *Pak J Biol Sci.* 2011;14:584–589.

35. Kuo SJ, Wang BB, Chang CS, et al. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER2/neu status in Taiwanese breast cancer patients. *Taiwan J Obstet Gynecol.* 2007;46:146–151.

36. Murthy SS, Sandhya DG, Ahmed F, et al. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. *Indian J Pathol Microbiol.* 2011;54:532–538.